Erasca, Inc. (ERAS) Financials

ERAS Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 419.4 million 80.4 million
2023-06-30 440.7 million 78.0 million
2023-03-31 467.5 million 81.1 million
2022-12-31 514.9 million 103.1 million

ERAS Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 -24.4 million 6.2 million
2023-06-30 -26.2 million 7.0 million
2023-03-31 -47.6 million 6.8 million
2022-12-31 -27.2 million 5.4 million

ERAS Net Income

No data available :(

ERAS Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 343.6 million - 56.8 million
2023-06-30 317.2 million - 57.6 million
2023-03-31 389.7 million - 58.1 million
2022-12-31 435.6 million - 55.1 million

ERAS Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 150.5 million
2023-06-30 150.0 million
2023-03-31 149.5 million
2022-12-31 127.5 million

ERAS Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 240000 25.2 million 9.4 million -
2023-06-30 247000 26.2 million 9.8 million -
2023-03-31 21.2 million 27.6 million 9.4 million -
2022-12-31 864000 29.4 million 8.7 million -

ERAS Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 - 941000
2023-06-30 - 955000
2023-03-31 - 894000
2022-12-31 - 933000

ERAS

Price: $2.18

52 week price:
1.51
3.38

Earnings Per Share: -0.83 USD

P/E Ratio: -1.02

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 393750

Market Capitalization: 346.0 million

Links: